Henan Key Laboratory for Molecular Nuclear Medicine and Translational Medicine, Department of Nuclear Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Department of Pathology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Sci Rep. 2024 Nov 5;14(1):26786. doi: 10.1038/s41598-024-78459-3.
Accurate postoperative assessment is critical for optimizing I therapy in patients with papillary thyroid cancer (PTC). This study aimed to develop a pathology model utilizing postoperative digital pathology slides to predict lymph node and/or distant metastases on post-therapeutic I scan after initial I treatment in PTC patients. A retrospective analysis was conducted on 229 PTC patients who underwent total or near-total thyroidectomy and subsequent I treatment after levothyroxine (LT4) withdrawal between January 2022 and August 2023. The pathology model was developed through two stages: patch-level prediction and WSI-level prediction. The clinical model was constructed using statistically significant variables identified from univariate and multivariate logistic regression analysis. Of the 229 patients, 19.6% (45/229) exhibited I-avid metastatic foci in post-therapeutic I scan. Multifactorial analysis identified stimulated thyroglobulin (sTg) as the sole independent risk factor. The AUC of the pathology model in the training and test cohorts were 0.976 (95% CI 0.948-1.000) and 0.805 (95% CI 0.660-0.951), respectively, which were significantly higher than the clinical model (AUC 0.652 and 0.548, Pall < 0.05). This model has the potential to serve as a valuable tool for clinicians in tailoring treatment strategies, thereby optimizing therapeutic outcomes for PTC patients.
准确的术后评估对于优化甲状腺乳头状癌 (PTC) 患者的碘治疗至关重要。本研究旨在开发一种利用术后数字病理切片的病理模型,预测 PTC 患者初始碘治疗后治疗性碘扫描中淋巴结和/或远处转移的可能性。对 2022 年 1 月至 2023 年 8 月期间接受全甲状腺切除术或近全甲状腺切除术且随后在停用左甲状腺素 (LT4) 后接受碘治疗的 229 例 PTC 患者进行了回顾性分析。病理模型通过两阶段开发:斑块级预测和 WSI 级预测。临床模型是使用单变量和多变量逻辑回归分析确定的统计学显著变量构建的。在 229 例患者中,19.6%(45/229)在治疗性碘扫描中显示碘摄取转移灶。多因素分析确定刺激甲状腺球蛋白 (sTg) 是唯一的独立危险因素。训练集和测试集中病理模型的 AUC 分别为 0.976(95%CI 0.948-1.000)和 0.805(95%CI 0.660-0.951),明显高于临床模型(AUC 0.652 和 0.548,Pall<0.05)。该模型有望成为临床医生制定治疗策略的有价值工具,从而优化 PTC 患者的治疗效果。